Daniel Shu
Impact in
-
- Immunotherapy and Immune Responses
- interferon and immune responses
- Immune Cell Function and Interaction
- Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 5
- Cancer Immunotherapy and Biomarkers 4
-
- Respiratory viral infections research 2
- Influenza Virus Research Studies 2
- Cytomegalovirus and herpesvirus research 1
- Co-authors
- Mark Yarchoan (7 shared papers)Luciane T. Kagohara (3 shared papers)Elizabeth M. Jaffee (3 shared papers)Philip L. Cohen (2 shared papers)Brendan Hilliard (2 shared papers)Wen-Hai Shao (2 shared papers)Yuxuan Zhen (1 shared paper)David B. Weiner (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)Nature Medicine (1 paper)Arthritis & Rheumatology (1 paper)Influenza and Other Respiratory Viruses (1 paper)Human Vaccines & Immunotherapeutics (1 paper)
- Partner nations
- United StatesSwitzerlandBelgium
In The Last Decade
Daniel Shu
15 papers receiving 347 citations
Daniel Shu's Hit Papers
Peers
Comparison fields: 5 of 52
- Immunology 141
- Hepatology 46
- Oncology 103
- Epidemiology 93
- Virology 11
Countries citing papers authored by Daniel Shu
This map shows the geographic impact of Daniel Shu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Shu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Shu more than expected).
Fields of papers citing papers by Daniel Shu
This network shows the impact of papers produced by Daniel Shu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Shu. The network helps show where Daniel Shu may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Shu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial Hit paper breakdown → | 2024 | 134 |
| 2 | 2016 | 59 | |
| 3 | 2017 | 47 | |
| 4 | 2022 | 39 | |
| 5 | 2011 | 28 | |
| 6 | 2023 | 22 | |
| 7 | 2025 | 6 | |
| 8 | 2024 | 3 | |
| 9 | 2012 | 3 | |
| 10 | 2022 | 3 | |
| 11 | 2022 | 2 | |
| 12 | 2023 | 2 | |
| 13 | 2024 | 2 | |
| 14 | [IFN-r/IL-4 expression in peripheral blood mononuclear cells of the patients with chronic severe hepatitis]. | 2001 | 1 |
| 15 | 2014 | 1 |
About Daniel Shu
Daniel Shu is a scholar working on Oncology, Epidemiology, Immunology, Pulmonary and Respiratory Medicine and Hepatology, having authored 15 papers that have together received 352 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Ferroptosis and cancer prognosis (2 papers), Immunotherapy and Immune Responses (2 papers), Respiratory viral infections research (2 papers), Influenza Virus Research Studies (2 papers), Cytomegalovirus and herpesvirus research (1 paper) and Cholangiocarcinoma and Gallbladder Cancer Studies (1 paper). The work is most often cited by research in Immunology (141 citations), Hepatology (46 citations), Oncology (103 citations), Epidemiology (93 citations) and Virology (11 citations). Daniel Shu has collaborated with scholars based in United States, Switzerland and Belgium. Frequent co-authors include Mark Yarchoan, Luciane T. Kagohara, Elizabeth M. Jaffee, Philip L. Cohen, Brendan Hilliard, Wen-Hai Shao, Yuxuan Zhen, David B. Weiner, Josette Northcott and Renzo Perales‐Linares. Their work appears in journals such as Journal of Clinical Oncology, Nature Medicine, Arthritis & Rheumatology, Influenza and Other Respiratory Viruses and Human Vaccines & Immunotherapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.